ArticleCureus2026
Role of Bone Turnover Markers and Bone Mineral Density in Monitoring Bone Health at One- and Three-Year Post-antiresorptive Therapy Initiation in Patients With Osteoporosis: A Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The gold-standard assessment of bone health is bone mineral density (BMD) measurement using dual-energy X-ray absorptiometry (DEXA); however, this modality is limited in its ability to detect short-term changes. Bone turnover markers (BTMs), specifically serum C-terminal telopeptide of type I collagen (CTX) and procollagen type I N-terminal propeptide (P1NP), offer the advantage of more frequent monitoring, yet their reliability as surrogate markers of bone health remains uncertain. This study investigates the relationship between BTMs and BMD during osteoporosis treatment. Methods Records of 214 patients treated at the Central Coast Osteoporosis Refracture Prevention (ORP) Clinic between June 2018 and May 2023 were reviewed. The relationship between BMD change (∆BMD) and changes in the levels and ratio of BTMs (∆BTM), specifically the propeptide of type I procollagen (P1NP) and the b-C-terminal telopeptide of type I collagen (CTX), at one-year and three-year post-treatment initiation was assessed. Simple statistical analysis and evaluation of the correlation coefficient were performed, including group stratification into clinically stable and clinically positive ∆BMD. A secondary analysis also stratified patients into those treated with IV versus oral bisphosphonates, using analysis of variance to compare the average change in BTM. Results Correlations between ∆BMD at all sites and ∆BTMs or the P1NP:CTX ratio were weak and not significant at one year. BTMs generally decreased with BMD improvement. There was no significant difference in BTM change over one to three years between patients with BMD improvement and those with BMD stability. However, ∆CTX was significantly greater in the improvement group in zoledronic acid (ZA)-medicated patients. These patients also had significant BMD changes at the hip and spine. ∆BTMs reached the clinical least significant change (LSC) with both medications. Conclusions Changes in BTMs and the P1NP:CTX ratio appear poorly correlated with medium- to long-term BMD changes. BTMs could potentially indicate therapeutic efficacy early in treatment, CTX perhaps more reliably than P1NP. Attainment of the LSC may more accurately predict BMD improvement than the magnitude of ∆BTMs. ZA may improve BMD more than oral bisphosphonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.